Similarly, ACBI3 is a pan-KRAS PROTAC degrader active against 13 of 17 of the most common KRAS mutations; it demonstrated potent and durable inhibition of KRAS signaling in vitro and tumor regression in vivo (157). The gene discussed is KRAS; the disease is neoplasm.